Abstracts tagged "Inflammation"

Abstract Number: 0878 • ACR Convergence 2024
YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease
vinod kumar, Tammana Sharma, Rahul Mahajan, Tarun Narang, Sunil Dogra and Sanjeev handa, PGIMER, Chandigarh, Chandigarh, India
Background/Purpose: Psoriasis is an inflammatory skin disease that progresses and worsens if left unattended. IL17 plays a pivotal role as a pathogenic trigger. Despite Th17…
Abstract Number: 0991 • ACR Convergence 2024
Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations
Varinder Hans¹, Don Voaklander¹, C. Allyson Jones² and Elaine Yacyshyn², ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Sarcoidosis is a granulomatous inflammatory response thought to be due to a dysregulated immune response to environmental antigens.1 The prevalence of sarcoidosis varies geographically.…
Abstract Number: 1579 • ACR Convergence 2024
Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis
Omar Mourad¹, Saif Abu Baker¹, Georges Khattar², Jennifer Jdaidani³, Khalil El-Gharib³ and Ahmad Mustafa³, ¹Staten Island University Hospital- Northwell Health, Staten Island, NY, ²Staten Island University Hospital, Staten Island, NY, ³Staten Island University Hospital- Northwell Health, Staten Island
Background/Purpose: Systemic sclerosis (SS) is a complex autoimmune rheumatic disease characterized by immune-mediated activation of both innate and adaptive immunity. Pulmonary involvement, specifically pulmonary arterial…
Abstract Number: 1838 • ACR Convergence 2024
M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases
Michelle Downing¹, Ling Zhang¹, Aditee Desphpande¹, Hong Zhang¹, Ohad Tarcic², Mira toister-achituv², Alec Gross³, Gang Chen³ and Chia Chi Sun¹, ¹EMD Serono Research and Development Institute, Inc., Billerica, MA, ²Inter-lab Ltd, Merck KGaA, Yavne, Israel, ³EMD Serono Reserch and Development Institute, Inc, Billerica, MA
Background/Purpose: Overactive adaptive immune responses contribute to many autoimmune diseases such as systemic lupus erythematosus (SLE). Chronically activated autoreactive T-effector cells play a pivotal role…
Abstract Number: 2078 • ACR Convergence 2024
Increased RAGE Expression in Myositis
Madison King¹, Rita Spathis², Elizabeth Bagley¹ and Melissa Morales³, ¹Binghamton University, Johnson City, NY, ²Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, ³SUNY Binghamton, Johnson City, NY
Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
Abstract Number: 2569 • ACR Convergence 2024
A Novel Hyperferritinemia Screen to Aid Differentiation of Hyperinflammatory Disorders
Hallie Carol¹, Adam Mayer², Jemy Varghese³, Zachary Martinez⁴, Caroline Diorio⁴, Paul Tsoukas⁵, Kate Kernan⁶ and Scott Canna⁷, ¹Children's Hospital of Philadelphia, Philadelphia, ²University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Pediatric Rheumatology, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁴Division of Pediatric Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁵Hospital for Sick Children/University of Toronto, Toronto, ON, Canada, ⁶Department of Critical Care Medicine, University of Pittsburgh School of Medicine, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, ⁷Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: High ferritin is an important and sensitive biomarker for the diverse and deadly group of cytokine storm syndromes grouped together under the term hemophagocytic…
Abstract Number: 0042 • ACR Convergence 2024
Modulating Inflammation and Angiogenesis in an Advanced 3D Rheumatoid Arthritis Synovial Tissue Model
Eva Philippon¹, Jan Piet van Hamburg¹, Lisanne van Rooijen¹, Gary Sims², Conny Van der Laken³ and Sander Tas⁴, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ³Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ⁴Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder characterized by chronic and destructive joint inflammation. Key features of RA include synovial cell…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 0567 • ACR Convergence 2024
Alteration of JAK-STAT Signaling in an Axial Spondyloarthritispatient with TYK2 Variants
Pankaj Sharma¹, Fatemeh Navid¹, Norman Watts¹, Stephen Brooks² and Robert Colbert², ¹National Institutes of Health, Bethesda, MD, ²NIH/NIAMS, Bethesda, MD
Background/Purpose: Tyrosine kinase 2 (TYK2) is a member of the Janus kinase family that associates with the cytoplasmic domain of type I/II cytokine receptors and…
Abstract Number: 0880 • ACR Convergence 2024
Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
Charles Besidonne¹, Andrew Benest¹, Kim Chisholm¹, Jonathan Morris², Lucy Donaldson³, Jeanette Woolard⁴ and David Bates¹, ¹University of Nottingham, Nottingham, United Kingdom, ²University of New South Wales, New South Wales, New South Wales, Australia, ³Versus Arthritis UK, Nottingham, United Kingdom, ⁴University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…
Abstract Number: 0996 • ACR Convergence 2024
Myocarditis Following Pfizer-BioNTech BNT162b2 Vaccine: Epidemiology and Predisposition
Enelle Mevorach, Adi Tabib and Dror Mevorach, Hadassah-University Hospital, Jerusalem, Israel
Background/Purpose: Following Pfizer-BioNTech BNT162b2 vaccine authorization, Israel initiated a nationwide COVID-19 vaccination campaign. The vaccine caused a higher incidence of myocarditis in young males. Here,…
Abstract Number: 1635 • ACR Convergence 2024
Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management
Matthias Froehlich¹, Michael Gernert², Marc Schmalzing³, Patrick-Pascal Strunz⁴, Hanna Labinsky⁵, Thorsten A. Bley⁶ and Konstanze V. Guggenberger⁶, ¹Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ²Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ³University Hospital Wuerzburg, Würzburg, Germany, ⁴University hospital of Wuerzburg, Wuerzburg, Germany, ⁵University Hospital Würzburg, Wuerzburg, Germany, ⁶University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Imaging techniques such as magnetic resonance imaging (MRI) are a cornerstone for the diagnosis of giant cell arteritis (GCA). In the further course of…
Abstract Number: 1920 • ACR Convergence 2024
Admixture Mapping and Gene-Based Analysis Identifies Rare Variants in Genes in the IL-13 and TGFβ Signaling Pathways in African Americans with Systemic Sclerosis
Jordan Hicks¹, Daniel Shriner², Ami Shah³, Maureen Mayes⁴, Ayo P. Doumatey², Amy R. Bentley¹, Robyn Domsic⁵, Thomas Medsger, Jr⁶, Paula Ramos⁷, Richard Silver⁸, Virginia Steen⁹, John Varga¹⁰, Vivien Hsu¹¹, Lesley Ann Saketkoo¹², Dinesh Khanna¹⁰, Elena Schiopu¹³, Jessica Gordon¹⁴, Lindsey Criswell¹⁵, Heather Gladue¹⁶, Chris Derk¹⁷, Elana Bernstein¹⁸, S. Louis Bridges¹⁴, Victoria Shanmugam¹⁹, Lorinda Chung²⁰, Suzanne Kafaja²¹, Reem Jan²², Marcin Trojanowski²³, Avram Goldberg²⁴, Benjamin Korman²⁵, James W. Thomas²⁶, Elaine Remmers²⁷, Adebowale Adeyemo², Charles Rotimi², Fredrick Wigley²⁸, Francesco Boin²⁹, Daniel Kastner³⁰ and Pravitt Gourh³¹, ¹National institute of Health, Bethesda, MD, ²Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ⁷Medical University of South Carolina, Charleston, SC, ⁸Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹²New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹³Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁴Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁵Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁶Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ¹⁹NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²⁰Stanford University, Woodside, CA, ²¹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²²Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²³Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁴NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁵University of Rochester, Rochester, NY, ²⁶NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²⁷Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²⁸Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ²⁹Cedars-Sinai Medical Center, Los Angeles, CA, ³⁰National Human Genome Research Institute, Bethesda, MD, ³¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD
Background/Purpose: There are significant racial disparities in systemic sclerosis (SSc), with an increased disease burden and worse outcomes among African American (AA) individuals. Reasons for…
Abstract Number: 2079 • ACR Convergence 2024
Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study
Silvia Grazzini¹, Angeles Galindo-Feria², Edoardo Conticini¹, Ingrid Lundberg³ and Maryam Dastmalchi⁴, ¹Università di Siena, Siena, Italy, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska University hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
Abstract Number: 2574 • ACR Convergence 2024
Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children
Mariia Pavlenko¹, Ilaria Maccora², Mekibib Altaye³, hermine brunner⁴, Alexandra Duell³, Megan Quinlan-Waters³, Alyssa Sproles¹, Sherry Thornton⁵, Virginia Miraldi Utz³ and sheila Angeles-Han⁶, ¹Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Childhood chronic anterior uveitis (CAU) can be idiopathic (iCAU) or associated with Juvenile Idiopathic Arthritis (JIA-U). Ocular complications occur in 50% of affected children. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.